BRCA MASTR DX

一個(gè)簡單的，強(qiáng)大的，完整的經(jīng)過CE-IVD認(rèn)證的診斷試劑組:

測試乳腺癌和卵巢癌的檢測在MPS。(NGS)

BRCA MASTR™Dx是一種分子診斷檢測中的編碼區(qū)的BRCA 1＆2的基因表達(dá)與乳腺癌，卵巢癌和/或相關(guān)的癌癥的風(fēng)險(xiǎn)增加的個(gè)人識(shí)別突變。Multiplicom的BRCA MASTR™Dx是準(zhǔn)備使用，並提供了強(qiáng)大的性能與zui低手中的時(shí)間。93擴(kuò)增（289-430個(gè)基點(diǎn)），使複合擴(kuò)增所需的所有試劑都包括在內(nèi)，完整覆蓋所有BRCA 1和2的基因編碼序列的外顯子的。該法是目前所有的大規(guī)模並行測序（MPS）平臺(tái)兼容，使您能夠靈活選擇您的首選方法。

幫助臨床醫(yī)生診斷，治療和管理乳腺癌和卵巢癌

BRCA1和BRCA2的突變與遺傳性乳腺癌和卵巢癌的發(fā)展。女性基因突變攜帶者，這兩種基因，有60％?80％一生中患乳腺癌的風(fēng)險(xiǎn)和20％?50％的卵巢癌的發(fā)展。男性BRCA2攜帶者有6％至8％的終身發(fā)展胰腺，肝，前列腺癌和乳腺癌的風(fēng)險(xiǎn)。家族史和年齡是zui重要的標(biāo)準(zhǔn)基因檢測要求。當(dāng)檢測到突變，有各種後續(xù)治療，如激素替代療法，化學(xué)預(yù)防策略和預(yù)防措施，臨床醫(yī)生可以提供降低乳腺癌/卵巢癌和整體死亡率。由於不同的治療方法，提供的各種BRCA基因突變的增加相關(guān)，Multiplicom BRCA MASTR™黴素的使用使得它的理想的測試方法由遺傳學(xué)家，以加快為臨床的早期診斷所需的信息和選擇測試治療可供選擇以增加他們的患者的存活率。

http://multiplicom.com/

Multiplicom launches new genomic and somatic mutation detection kits

Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massively parallel sequencing (MPS), has announced that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology.

The genomic kits enable PCR amplification of all coding regions of genes known to cause Mucovisidosis, Marfan syndrome, Alport syndrome, Polycystic Kidney Disease, Familial Mediterranean Fever and Duchenne Muscular Dystrophy through the identification of single nucleotide polymorphisms, small deletions/insertions and copy number variations. The EGFR MASTR kit is Multiplicom’s first somatic mutation detection product for the analysis of tumor tissue, targeting exons 18 to 21 of the EGFR gene, key to selecting the most effective treatment options.

These newly launched tests complement Multiplicom’s MASTR product line which can be used in combination with all benchtop MPS instruments. Earlier this month, Multiplicom started shipping BRCA MASTR Dx, its first CE/IVD labeled kit, and is in the process of qualifying other kits for EU regulatory approval.

Dr Dirk Pollet, CEO of Multiplicom, said: “The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in routine diagnostic labs. Multiplicom’s products are simple, easy to use, only require standard equipment and are compatible with MPS equipment from Roche, Life Technologies and Illumina.”

上海起發(fā)實(shí)驗(yàn)試劑有限公司
實(shí)驗(yàn)試劑一站式采購服務(wù)商
1：強(qiáng)大的進(jìn)口輻射能力，血清、抗體、耗材、大部分限制進(jìn)口品等。
2：產(chǎn)品種類齊全，經(jīng)營超過700多個(gè)品牌，基本涵蓋所有生物實(shí)驗(yàn)試劑耗材。
3：提供加急服務(wù)，貨品一般1-2周到貨。
4：富有競爭力的價(jià)格優(yōu)勢，絕大部分價(jià)格有優(yōu)勢。
5：多年積累良好的信譽(yù)，大部分客戶提供貨到付款服務(wù)?？蛻舭ㄇ迦A、北大、交大、復(fù)旦、中山等100多所高校，ROCHE，阿斯利康、國藥、fisher等藥企。
6：我們還是Santa,Advanced Biotechnologies Inc,Athens Research & Technology,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. FormuMax Scientific,Inc, Genebridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,omicronbio, Polysciences,prospecbi, QA-BIO,quickzyme,RESEARCH DIETS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國外公司授權(quán)代理。
7：我們還是invitrogen,qiagen,Tempshield, Inc.am,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等*批發(fā)，歡迎合作。